Skip to main content
Midas Edge

908 Devices Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

MASS$9.99-13.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders'
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ · Income (Loss) · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balances at December 31, 2025​36,321,866​$36​$366,925​$54​$(223,316)​$143,699
Issuance of common stock upon exercise of stock options​53,195​​—​​80​​—​​—​​80
Stock-based compensation expense​—​​—​​2,399​​—​​—​​2,399
Vesting of restricted stock units​1,038,792​​1​​(1)​​—​​—​​—
Net loss​—​​—​​—​​—​​(11,955)​​(11,955)
Unrealized loss on marketable securities​—​​—​​—​​(52)​​—​​(52)
Balances at March 31, 2026​37,413,853​$37​$369,403​$2​$(235,271)​$134,171
Issuance of common stock upon exercise of stock options​164,686​​—​​992​​—​​—​​992
Stock-based compensation expense​—​​—​​2,313​​—​​—​​2,313
Issuance of common stock pursuant to the acquisition of NIRLAB​263,472​​1​​1,725​​—​​—​​1,726
Issuance of common stock upon ESPP purchase​32,699​​—​​190​​—​​—​​190
Vesting of restricted stock units​184,298​​—​​—​​—​​—​​—
Net loss​—​​—​​—​​—​​(11,894)​​(11,894)
Unrealized loss on marketable securities​—​​—​​—​​(43)​​—​​(43)
Foreign currency translation adjustments​—​​—​​—​​(689)​​—​​(689)
Balances at June 30, 2026​38,059,008​$38​$374,623​$(730)​$(247,165)​$126,766
Issuance of common stock upon exercise of stock options​100,239​​—​​590​​—​​—​​590
Shares issued in settlement of contingent consideration​3,213,583​​3​​25,320​​—​​—​​25,323
Stock-based compensation expense​—​​—​​2,336​​—​​—​​2,336
Vesting of restricted stock units​46,184​​—​​—​​—​​—​​—
Net loss​—​​—​​—​​—​​(4,579)​​(4,579)
Unrealized loss on marketable securities​—​​—​​—​​(31)​​—​​(31)
Foreign currency translation adjustments​—​​—​​—​​(602)​​—​​(602)
Balances at September 30, 202641,419,014​$41​$402,869​$(1,363)​$(251,744)​$149,803
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-in · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders'
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ · Income (Loss) · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balances at December 31, 2024​35,098,493​$35​$356,216​$1,146​$(242,805)​$114,592
Issuance of common stock upon exercise of stock options8,266​​—​​11​​—​​—​​11
Stock-based compensation expense—​​—​​2,365​​—​​—​​2,365
Vesting of restricted stock units​632,797​​1​​—​​—​​—​​1
Net income—​​—​​—​​—​​43,603​​43,603
Foreign currency translation adjustments​—​​—​​—​​(7)​​—​​(7)
Foreign currency translation adjustments reclassed out of accumulated other comprehensive income related to discontinued operations​—​​—​​—​​(1,125)​​—​​(1,125)
Unrealized loss on marketable securities​—​​—​​—​​(16)​​—​​(16)
Balances at March 31, 2025​35,739,556​$36​$358,592​$(2)​$(199,202)​$159,424
Issuance of common stock upon exercise of stock options​100,397​​—​​207​​—​​—​​207
Stock-based compensation expense​—​​—​​2,336​​—​​—​​2,336
Issuance of common stock upon ESPP purchase​57,988​​—​​170​​—​​—​​170
Vesting of restricted stock units​159,635​​—​​—​​—​​—​​—
Net loss​—​​—​​—​​—​​(13,306)​​(13,306)
Unrealized loss on marketable securities​—​​—​​—​​(14)​​—​​(14)
Balances at June 30, 2025​36,057,576​$36​$361,305​$(16)​$(212,508)​$148,817
Issuance of common stock upon exercise of stock options24,746​​—​​26​​—​​—​​26
Stock-based compensation expense​—​​—​​2,379​​—​​—​​2,379
Vesting of restricted stock units​36,254​​—​​—​​—​​—​​—
Net loss​—​​—​​—​​—​​(14,982)​​(14,982)
Unrealized gains on marketable securities​—​​—​​—​​59​​—​​59
Balances at September 30, 2025​36,118,576​$36​$363,710​$43​$(227,490)​$136,299
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.